(Total Views: 769)
Posted On: 01/31/2022 6:51:43 PM
Post# of 148879
I'm with Cdiddy. Nearest news tidbits are likely from court filings or changes to clinical trials descriptions.
Add me to the list of those that appreciate having Brendan Rae back. He grew up with about 7 years in big pharma. Has a law degree. Was at CYDY for over a year ending August 2020, then appears to have become US bus dev head for a major Chinese generic maker that also mentions biosimilars - so MABs.
Why did he leave? What brought him back 3 months ago? A change of heart at the Board about deals? At least he isn't starting from ground zero.
My view of what's next? How nice of you to ask!
If I'm selling something with a mixed track record, I'm selling how great it will be when the missing ingredient is added: That's obviously you, Mr. Uniquely-positioned-to-leverage-this-molecule big pharma, You!
OK, and your money. Now.
And, yes, I would definitely blame all shortcomings (faulty filings with the FDA and failing internal controls) on someone who won't be causing issues any more. As a bonus, nobody hates you! See the immediate upside, Mr. Buyer!
Hey, NP may have been Moses at some point, but even Moses had baggage that wasn't permitted to cross into the promised land. Unless we hear the firing was for cause, being fired is a great financial outcome for NP.
So, BP (or a SPAC, or ???), let's hear your bids for an indication, for the molecule as a whole, or even for a turnkey small-group, low-expense "company." Just bring your CEO - and your money.
With your special resources we lacked, and with prior hair being neatly shaved, success is assured! Bid up!
Add me to the list of those that appreciate having Brendan Rae back. He grew up with about 7 years in big pharma. Has a law degree. Was at CYDY for over a year ending August 2020, then appears to have become US bus dev head for a major Chinese generic maker that also mentions biosimilars - so MABs.
Why did he leave? What brought him back 3 months ago? A change of heart at the Board about deals? At least he isn't starting from ground zero.
My view of what's next? How nice of you to ask!
If I'm selling something with a mixed track record, I'm selling how great it will be when the missing ingredient is added: That's obviously you, Mr. Uniquely-positioned-to-leverage-this-molecule big pharma, You!
OK, and your money. Now.
And, yes, I would definitely blame all shortcomings (faulty filings with the FDA and failing internal controls) on someone who won't be causing issues any more. As a bonus, nobody hates you! See the immediate upside, Mr. Buyer!
Hey, NP may have been Moses at some point, but even Moses had baggage that wasn't permitted to cross into the promised land. Unless we hear the firing was for cause, being fired is a great financial outcome for NP.
So, BP (or a SPAC, or ???), let's hear your bids for an indication, for the molecule as a whole, or even for a turnkey small-group, low-expense "company." Just bring your CEO - and your money.
With your special resources we lacked, and with prior hair being neatly shaved, success is assured! Bid up!
(13)
(0)Scroll down for more posts ▼
